Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 3
1975 27
1976 84
1977 134
1978 173
1979 195
1980 220
1981 244
1982 221
1983 246
1984 266
1985 294
1986 292
1987 273
1988 223
1989 218
1990 237
1991 231
1992 250
1993 201
1994 185
1995 179
1996 172
1997 173
1998 147
1999 128
2000 141
2001 107
2002 116
2003 90
2004 80
2005 98
2006 118
2007 93
2008 75
2009 80
2010 92
2011 93
2012 88
2013 117
2014 92
2015 103
2016 88
2017 109
2018 104
2019 92
2020 100
2021 101
2022 87
2023 71
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

7,151 results

Results by year

Filters applied: . Clear all
Page 1
Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis.
Tang Y, Ponandai-Srinivasan S, Frisendahl C, Andersson JK, Pavone D, Stewart EA, Lalitkumar PGL, Korsching E, Bogavarappu NR, Gemzell-Danielsson K. Tang Y, et al. Front Endocrinol (Lausanne). 2023 Mar 9;14:1026168. doi: 10.3389/fendo.2023.1026168. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36967761 Free PMC article.
OBJECTIVE: Bromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical trial. ...Small RNA sequencing was applied on tissues collected from women with adenomyosis before and after bromocriptine treatment …
OBJECTIVE: Bromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical …
Bromocriptine in Parkinson disease.
Lieberman AN, Goldstein M. Lieberman AN, et al. Pharmacol Rev. 1985 Jun;37(2):217-27. Pharmacol Rev. 1985. PMID: 3901046 Review.
Bromocriptine, in low doses, is effective in patients with mild to moderate Parkinson's disease, while bromocriptine in higher doses is needed in patients with advanced disease. Both in low doses and in high doses, bromocriptine combined with levodopa is usua …
Bromocriptine, in low doses, is effective in patients with mild to moderate Parkinson's disease, while bromocriptine in higher …
Bromocriptine in the treatment of parkinsonism.
Parkes JD. Parkes JD. Drugs. 1979 May;17(5):365-82. doi: 10.2165/00003495-197917050-00006. Drugs. 1979. PMID: 37066 Review.
Bromocriptine alters the motor behaviour of animals and improves the motor defect of parkinsonism. Changes in movement are accompanied by biochemical changes in the central nervous system, consistent with the idea that bromocriptine has a dopamine agonist action in …
Bromocriptine alters the motor behaviour of animals and improves the motor defect of parkinsonism. Changes in movement are accompanie …
Drugs five years later. Bromocriptine.
Vance ML, Evans WS, Thorner MO. Vance ML, et al. Ann Intern Med. 1984 Jan;100(1):78-91. doi: 10.7326/0003-4819-100-1-78. Ann Intern Med. 1984. PMID: 6229205 Review.
Bromocriptine, a specific dopamine receptor agonist, has been used for the treatment of various hyperprolactinemic conditions and as adjunctive therapy for acromegaly (with or without concomitant hyperprolactinemia) and Parkinson's disease. Bromocriptine is extremel …
Bromocriptine, a specific dopamine receptor agonist, has been used for the treatment of various hyperprolactinemic conditions and as …
Bromocriptine for unexplained subfertility in women.
Hughes E, Collins J, Vandekerckhove P. Hughes E, et al. Cochrane Database Syst Rev. 2000;(2):CD000044. doi: 10.1002/14651858.CD000044. Cochrane Database Syst Rev. 2000. PMID: 10796473 Updated. Review.
BACKGROUND: Bromocriptine improves hyperprolactinemic amenorrhea and so could also be helpful in the treatment of unexplained subfertility in women. ...SELECTION CRITERIA: Randomised trials comparing bromocriptine with placebo or no treatment in women with unexplain …
BACKGROUND: Bromocriptine improves hyperprolactinemic amenorrhea and so could also be helpful in the treatment of unexplained subfert …
Repurposing of Bromocriptine for Cancer Therapy.
Seo EJ, Sugimoto Y, Greten HJ, Efferth T. Seo EJ, et al. Front Pharmacol. 2018 Oct 8;9:1030. doi: 10.3389/fphar.2018.01030. eCollection 2018. Front Pharmacol. 2018. PMID: 30349477 Free PMC article.
Bromocriptine strongly bound to NF-kappaB pathway proteins as shown by molecular docking and interacted more strongly with DNA-bound NF-kappaB than free NF-kappaB, indicating that bromocriptine may inhibit NF-kappaB binding to DNA. Furthermore, bromocriptine …
Bromocriptine strongly bound to NF-kappaB pathway proteins as shown by molecular docking and interacted more strongly with DNA-bound …
Bromocriptine: does this drug of Parkinson's disease have a role in managing cardiovascular diseases?
Kutikuppala LVS, Sharma S, Chavan M, Rangari G, Misra AK, Innamuri SR, Vijayakumar T, Varshitha G. Kutikuppala LVS, et al. Ann Med Surg (Lond). 2023 Dec 19;86(2):926-929. doi: 10.1097/MS9.0000000000001642. eCollection 2024 Feb. Ann Med Surg (Lond). 2023. PMID: 38333315 Free PMC article. Review.
Apart from prolactin inhibiting action, bromocriptine has some beneficial effects on the blood pressure, plasma norepinephrine levels and vascular resistance. ...Bromocriptine is mainly contraindicated in patients with syncope with hypotension, psychosis, and type I …
Apart from prolactin inhibiting action, bromocriptine has some beneficial effects on the blood pressure, plasma norepinephrine levels …
Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
Siamashvili M, Davis S. Siamashvili M, et al. Expert Opin Pharmacother. 2021 Feb;22(2):241-247. doi: 10.1080/14656566.2020.1825683. Epub 2020 Oct 8. Expert Opin Pharmacother. 2021. PMID: 33030357 Review.
INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally acting drug that can be used for the treatment of adults with type 2 diabetes. ...EXPERT OPINION: Efficacy of bromocriptine mesylate Q …
INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally a …
Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.
Yang Y, Mamouni K, Li X, Chen Y, Kavuri S, Du Y, Fu H, Kucuk O, Wu D. Yang Y, et al. Mol Cancer Ther. 2018 Sep;17(9):1859-1870. doi: 10.1158/1535-7163.MCT-17-1176. Epub 2018 Jun 15. Mol Cancer Ther. 2018. PMID: 29907594 Free PMC article.
At the molecular level, bromocriptine inhibits the expression of c-Myc, E2F-1, and survivin and increases the expression of p53, p21, and p27. Intriguingly, bromocriptine markedly reduces androgen receptor levels, partially through Hsp90-mediated protein degradation …
At the molecular level, bromocriptine inhibits the expression of c-Myc, E2F-1, and survivin and increases the expression of p53, p21, …
The motor effects of bromocriptine--a review.
Jackson DM, Jenkins OF, Ross SB. Jackson DM, et al. Psychopharmacology (Berl). 1988;95(4):433-46. doi: 10.1007/BF00172952. Psychopharmacology (Berl). 1988. PMID: 3145515 Review.
For many years, bromocriptine has proven to be a useful treatment for some of the disabling motor effects seen in Parkinson's disease. ...It closes with a consideration of several remaining unsolved problems associated with the pharmacology of bromocriptine and sugg …
For many years, bromocriptine has proven to be a useful treatment for some of the disabling motor effects seen in Parkinson's disease …
7,151 results